prednisone has been researched along with granisetron in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujii, H; Horiike, S; Iwai, T; Kaneko, H; Kashima, K; Misawa, S; Nakagawa, H; Nakao, M; Nakazawa, N; Ookawara, Y; Sasai, Y; Tamura, A; Taniwaki, M; Tsuda, S; Ueda, Y; Yokota, S | 1 |
| Bleuse, JP; Block, S; Bonneterre, J; Bonneterre, ME; Carlier, D; Darloy, F; Fournier, C; Huc, P | 1 |
| Bauduer, F; Coiffier, B; Desablens, B | 1 |
| Leelasiri, A; Mongkonsritragoon, W; Numbenjapon, T; Prayoonwiwat, W; Sriswasdi, C | 1 |
| Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M | 1 |
1 review(s) available for prednisone and granisetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for prednisone and granisetron
| Article | Year |
|---|---|
[Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Serotonin Antagonists; Vincristine; Vomiting | 1998 |
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Female; Granisetron; Humans; Male; Methotrexate; Nausea; Ondansetron; Prednisone; Vindesine; Vomiting | 1998 |
Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Doxorubicin; Epirubicin; Female; Granisetron; Humans; Lymphoma; Male; Middle Aged; Prednisone; Vomiting | 1999 |
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cross-Over Studies; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Metoclopramide; Middle Aged; Nausea; Patient Satisfaction; Prednisone; Probability; Treatment Outcome; Vincristine; Vomiting | 2002 |
6 other study(ies) available for prednisone and granisetron
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Topics: Adult; Aged; Aging; Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Doxorubicin; Female; Granisetron; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prednisone; Quinuclidines; Risk Factors; Rituximab; Sex Characteristics; Treatment Outcome; Vincristine; Vomiting; Young Adult | 2017 |